These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 19552895)

  • 21. Incorporation of LpxL1, a detoxified lipopolysaccharide adjuvant, in influenza H5N1 virosomes increases vaccine immunogenicity.
    de Vries JJ; Bungener L; Ter Veer W; van Alphen L; van der Ley P; Wilschut J; Huckriede A
    Vaccine; 2009 Feb; 27(6):947-55. PubMed ID: 19059296
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vaxfectin enhances both antibody and in vitro T cell responses to each component of a 5-gene Plasmodium falciparum plasmid DNA vaccine mixture administered at low doses.
    Sedegah M; Rogers WO; Belmonte M; Belmonte A; Banania G; Patterson NB; Rusalov D; Ferrari M; Richie TL; Doolan DL
    Vaccine; 2010 Apr; 28(17):3055-65. PubMed ID: 19879998
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Two doses of parenterally administered split influenza virus vaccine elicited high serum IgG concentrations which effectively limited viral shedding upon challenge in mice.
    Hovden AO; Cox RJ; Madhun A; Haaheim LR
    Scand J Immunol; 2005 Oct; 62(4):342-52. PubMed ID: 16253121
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunopotentiation of Different Adjuvants on Humoral and Cellular Immune Responses Induced by HA1-2 Subunit Vaccines of H7N9 Influenza in Mice.
    Song L; Xiong D; Hu M; Kang X; Pan Z; Jiao X
    PLoS One; 2016; 11(3):e0150678. PubMed ID: 26930068
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protective effect of nasal immunization of influenza virus hemagglutinin with recombinant cholera toxin B subunit as a mucosal adjuvant in mice.
    Isaka M; Zhao Y; Nobusawa E; Nakajima S; Nakajima K; Yasuda Y; Matsui H; Hasegawa T; Maeyama J; Morokuma K; Ohkuma K; Tochikubo K
    Microbiol Immunol; 2008 Feb; 52(2):55-63. PubMed ID: 18380802
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship between structure and adjuvanticity of N,N,N-trimethyl chitosan (TMC) structural variants in a nasal influenza vaccine.
    Hagenaars N; Verheul RJ; Mooren I; de Jong PH; Mastrobattista E; Glansbeek HL; Heldens JG; van den Bosch H; Hennink WE; Jiskoot W
    J Control Release; 2009 Dec; 140(2):126-33. PubMed ID: 19712713
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intranasal interleukin-12 is a powerful adjuvant for protective mucosal immunity.
    Arulanandam BP; O'Toole M; Metzger DW
    J Infect Dis; 1999 Oct; 180(4):940-9. PubMed ID: 10479116
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A new intranasal influenza vaccine based on a novel polycationic lipid-ceramide carbamoyl-spermine (CCS). II. Studies in mice and ferrets and mechanism of adjuvanticity.
    Even-Or O; Joseph A; Itskovitz-Cooper N; Samira S; Rochlin E; Eliyahu H; Goldwaser I; Balasingam S; Mann AJ; Lambkin-Williams R; Kedar E; Barenholz Y
    Vaccine; 2011 Mar; 29(13):2474-86. PubMed ID: 21251901
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The humoral immune response and protective efficacy of vaccination with inactivated split and whole influenza virus vaccines in BALB/c mice.
    Cox RJ; Hovden AO; Brokstad KA; Szyszko E; Madhun AS; Haaheim LR
    Vaccine; 2006 Nov; 24(44-46):6585-7. PubMed ID: 16839650
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lipid vesicle size of an oral influenza vaccine delivery vehicle influences the Th1/Th2 bias in the immune response and protection against infection.
    Mann JF; Shakir E; Carter KC; Mullen AB; Alexander J; Ferro VA
    Vaccine; 2009 Jun; 27(27):3643-9. PubMed ID: 19464545
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaxfectin enhances immunogenicity and protective efficacy of P. yoelii circumsporozoite DNA vaccines.
    Sedegah M; Rogers WO; Belmonte A; Belmonte M; Banania G; Patterson N; Ferrari M; Kaslow DC; Carucci DJ; Richie TL; Doolan DL
    Vaccine; 2006 Mar; 24(11):1921-7. PubMed ID: 16298024
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The novel adjuvant CoVaccineHT increases the immunogenicity of cell-culture derived influenza A/H5N1 vaccine and induces the maturation of murine and human dendritic cells in vitro.
    Bodewes R; Geelhoed-Mieras MM; Heldens JG; Glover J; Lambrecht BN; Fouchier RA; Osterhaus AD; Rimmelzwaan GF
    Vaccine; 2009 Nov; 27(49):6833-9. PubMed ID: 19772942
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influenza hemagglutinin vaccine with poly(gamma-glutamic acid) nanoparticles enhances the protection against influenza virus infection through both humoral and cell-mediated immunity.
    Okamoto S; Yoshii H; Akagi T; Akashi M; Ishikawa T; Okuno Y; Takahashi M; Yamanishi K; Mori Y
    Vaccine; 2007 Nov; 25(49):8270-8. PubMed ID: 17977633
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Zymosan enhances the mucosal adjuvant activity of poly(I:C) in a nasal influenza vaccine.
    Ainai A; Ichinohe T; Tamura S; Kurata T; Sata T; Tashiro M; Hasegawa H
    J Med Virol; 2010 Mar; 82(3):476-84. PubMed ID: 20087927
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge.
    Jimenez GS; Planchon R; Wei Q; Rusalov D; Geall A; Enas J; Lalor P; Leamy V; Vahle R; Luke CJ; Rolland A; Kaslow DC; Smith LR
    Hum Vaccin; 2007; 3(5):157-64. PubMed ID: 17637571
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhancement of immune responses to influenza vaccine (H3N2) by ginsenoside Re.
    Song X; Chen J; Sakwiwatkul K; Li R; Hu S
    Int Immunopharmacol; 2010 Mar; 10(3):351-6. PubMed ID: 20034596
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity and protective efficacy of a vaxfectin-adjuvanted tetravalent dengue DNA vaccine.
    Porter KR; Ewing D; Chen L; Wu SJ; Hayes CG; Ferrari M; Teneza-Mora N; Raviprakash K
    Vaccine; 2012 Jan; 30(2):336-41. PubMed ID: 22085548
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of influenza vaccine formulation with a detailed analysis of the cytokine response.
    Szyszko E; Brokstad K; Cox RJ; Hovden AO; Madhun A; Haaheim LR
    Scand J Immunol; 2006 Nov; 64(5):467-75. PubMed ID: 17032238
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine.
    Cooper CL; Davis HL; Morris ML; Efler SM; Krieg AM; Li Y; Laframboise C; Al Adhami MJ; Khaliq Y; Seguin I; Cameron DW
    Vaccine; 2004 Aug; 22(23-24):3136-43. PubMed ID: 15297066
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of biomarkers after intramuscular injection of Vaxfectin-formulated hCMV gB plasmid DNA.
    Vilalta A; Shlapobersky M; Wei Q; Planchon R; Rolland A; Sullivan S
    Vaccine; 2009 Dec; 27(52):7409-17. PubMed ID: 19735757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.